Catalent's acquisition by Novo Holdings faces regulatory updates. UK sees a preference for Mounjaro over Wegovy. This image ...

Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, 4 ...

Meanwhile, major financial dealings unfold as McKinsey settles a lawsuit over its opioid crisis advice for Purdue Pharma, and ...

Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...

Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...

Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy. According to the ...

Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod ...

Danish pharma giant Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, is set to boost production with a ...

Abbott today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an increase of 7.3%. The company's quarterly dividend payout has ...

Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.